175 related articles for article (PubMed ID: 24824038)
1. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance.
Moreel X; Allaire J; Léger C; Caron A; Labonté MÈ; Lamarche B; Julien P; Desmeules P; Têtu B; Fradet V
Cancer Prev Res (Phila); 2014 Jul; 7(7):766-76. PubMed ID: 24824038
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level.
Moussa H; Nguile-Makao M; Robitaille K; Guertin MH; Allaire J; Pelletier JF; Moreel X; Gevariya N; Diorio C; Desmeules P; Têtu B; Lamarche B; Julien P; Fradet V
Nutrients; 2019 Jul; 11(7):. PubMed ID: 31315273
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of tissue ω-6 and ω-3 polyunsaturated fatty acids (PUFA) in benign and malignant pathologic stage pT2a radical prostatectomy specimens.
Schumacher MC; Laven B; Petersson F; Cederholm T; Onelöv E; Ekman P; Brendler C
Urol Oncol; 2013 Apr; 31(3):318-24. PubMed ID: 21414816
[TBL] [Abstract][Full Text] [Related]
4. Prostate tissue and leukocyte levels of n-3 polyunsaturated fatty acids in men with benign prostate hyperplasia or prostate cancer.
Christensen JH; Fabrin K; Borup K; Barber N; Poulsen J
BJU Int; 2006 Feb; 97(2):270-3. PubMed ID: 16430627
[TBL] [Abstract][Full Text] [Related]
5. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men.
Ritch CR; Wan RL; Stephens LB; Taxy JB; Huo D; Gong EM; Zagaja GP; Brendler CB
J Urol; 2007 Jan; 177(1):97-101; discussion 101. PubMed ID: 17162011
[TBL] [Abstract][Full Text] [Related]
6. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.
Pandalai PK; Pilat MJ; Yamazaki K; Naik H; Pienta KJ
Anticancer Res; 1996; 16(2):815-20. PubMed ID: 8687134
[TBL] [Abstract][Full Text] [Related]
7. Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer.
Allaire J; Moreel X; Labonté MÈ; Léger C; Caron A; Julien P; Lamarche B; Fradet V
Eur J Clin Nutr; 2015 Sep; 69(9):1004-8. PubMed ID: 25758837
[TBL] [Abstract][Full Text] [Related]
8. [Dietary fatty acids and colorectal and prostate cancers: epidemiological studies].
Astorg P
Bull Cancer; 2005 Jul; 92(7):670-84. PubMed ID: 16123006
[TBL] [Abstract][Full Text] [Related]
9. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer.
Aronson WJ; Glaspy JA; Reddy ST; Reese D; Heber D; Bagga D
Urology; 2001 Aug; 58(2):283-8. PubMed ID: 11489728
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma.
Godley PA; Campbell MK; Gallagher P; Martinson FE; Mohler JL; Sandler RS
Cancer Epidemiol Biomarkers Prev; 1996 Nov; 5(11):889-95. PubMed ID: 8922296
[TBL] [Abstract][Full Text] [Related]
11. A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer.
Apte SA; Cavazos DA; Whelan KA; Degraffenried LA
Nutr Cancer; 2013; 65(4):556-62. PubMed ID: 23659447
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of intake of fish and marine fatty acids and prostate cancer.
Augustsson K; Michaud DS; Rimm EB; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):64-7. PubMed ID: 12540506
[TBL] [Abstract][Full Text] [Related]
13. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
[TBL] [Abstract][Full Text] [Related]
14. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
16. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
18. Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.
Freeman VL; Meydani M; Hur K; Flanigan RC
Cancer; 2004 Dec; 101(12):2744-54. PubMed ID: 15495177
[TBL] [Abstract][Full Text] [Related]
19. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
[TBL] [Abstract][Full Text] [Related]
20. Intake of total omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid and risk of coronary heart disease in the Spanish EPIC cohort study.
Amiano P; Machón M; Dorronsoro M; Chirlaque MD; Barricarte A; Sánchez MJ; Navarro C; Huerta JM; Molina-Montes E; Sánchez-Cantalejo E; Urtizberea M; Arriola L; Larrañaga N; Ardanaz E; Quirós JR; Moreno-Iribas C; González CA
Nutr Metab Cardiovasc Dis; 2014 Mar; 24(3):321-7. PubMed ID: 24360762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
